SUTRO BIOPHARMA, INC. (STRO) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2023-12-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2023-12-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2023-12-31..
Borrowing debt
Overview →Financial period ending 2023-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 4.06M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 0.00 USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 333.68M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 470.74M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | (m) | (m) | $4.06M | $0.00 | (m) | $333.68M | $470.74M | (m) |
| 2022-12-31 | (m) | (m) | $12.50M | $3.77M | (m) | $302.34M | $406.94M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $6.78M | (m) | $287.34M | $400.70M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $9.78M | (m) | $191.63M | $385.62M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $12.76M | (m) | $171.40M | $303.68M | (m) |
| 2021-12-31 | (m) | (m) | $9.38M | $15.74M | (m) | $160.76M | $341.41M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $18.71M | (m) | $189.94M | $371.47M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $21.69M | (m) | $223.42M | $359.79M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $24.68M | (m) | $220.27M | $358.53M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $24.55M | (m) | $326.49M | $394.11M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $24.41M | (m) | $202.36M | $307.24M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $24.28M | (m) | $201.36M | $277.54M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $24.16M | (m) | $115.39M | $153.88M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $8.88M | (m) | $117.86M | $156.37M | (m) |
| 2019-09-30 | (m) | (m) | (m) | $5.50M | (m) | $125.16M | $171.68M | (m) |
| 2019-06-30 | (m) | (m) | (m) | $7.00M | (m) | $153.16M | $188.81M | (m) |
| 2019-03-31 | (m) | (m) | (m) | $8.50M | (m) | $170.57M | $202.46M | (m) |
| 2018-12-31 | (m) | (m) | (m) | $10.00M | (m) | $204.49M | $223.14M | (m) |
| 2018-09-30 | (m) | (m) | (m) | $11.50M | (m) | $122.95M | $145.03M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |